Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system.

ABSTRACT:

Background

Ripretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation. This study analyzes real-world data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) to investigate adverse events (AEs) associated with ripretinib.

Methods

Adverse event reports (AERs) related to ripretinib were extracted from FAERS ASCII data spanning from the second quarter of 2020 to the second quarter of 2024. Following standardization, various disproportionality analyses, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), bayesian confidence propagation neural network (BCPNN), and empirical bayes geometr

SUBMITTER: Wang S 

PROVIDER: S-EPMC11994415 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature